Tradestie Institutional Equity Comparison Engine

IBB vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBB Overall Edge

IBB Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares Biotechnology ETF (IBB) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, IBB trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBB sits in UNCLASSIFIED (22nd %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IBB N/M vs CDT N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner IBB
1Y +20.8% vs -86.8% ยท 52W Pos 64% vs 2%
Options & Structure Winner IBB
UNCLASSIFIED (22nd %ile IV) vs BREAKDOWN (N/A IV)
IBB NASDAQ
iShares Biotechnology ETF
Institutional Equity
$199.54
-2.05% 1D
Market Cap N/A
1M Return -4.77%
1Y Return +20.77%
Forward P/E N/M
Unified AI Score
46.9 / 100 HOLD
Tech 27.0 Fund 47.0 Flow 50.0 Mom 56.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBB +20.77% CDT -86.78% Spread: +107.55 pp (IBB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBB TTM Op. Margin: N/A CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBB vs CDT. Trailing 12-month operating profitability (IBB N/A vs CDT 0.0%) and valuation multiples (IBB N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBB (3) vs CDT (5)
Institutional Metric IBB CDT Criterion Row Winner
Market Capitalization Scale N/A $507,528 Larger Scale CDT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth CDT
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin CDT
Net Profit Margin Profitability N/A 0.0% Higher Margin CDT
Return on Equity (ROE) Capital Efficiency N/A -69.7% Higher ROE CDT
52-Week Range Position Momentum 64% ($160โ€“$222) 2% ($0โ€“$11) Stronger Trend IBB
Beta / 30D Volatility Risk Regime 0.84ฮฒ ยท 29% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk IBB
Unified Institutional Score Composite Signal 46.9 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite IBB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBB vs CDT Buy Guide
IBB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live IBB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBB nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.